Vident Advisory’s Guardant Health GH Stock Holding History

Vident Advisory’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$237K	Buy	+1,578	New	+$172K	﹤0.01%	1715

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vident Advisory's GH Position: Q2 2026 in Review

Vident Advisory opened a new position in Guardant Health (GH) in Q2 2026: 1,578 shares worth $237K. The stake represents ﹤0.01% of the portfolio and ranks #1715 among its holdings.

597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

Vident Advisory held 1,578 shares of Guardant Health worth $237K as of Q2 2026.
Guardant Health was a new Vident Advisory position in Q2 2026.
Guardant Health made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1715 holding.
597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.